Cartesian Reports FY25 Revenue of $2.797M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy RNAC?
Reports FY25 revenue $2.797M, consensus $1.97M. "Building on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 across several autoimmune indications," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "Our top priority remains delivering on our Phase 3 AURORA trial in myasthenia gravis, for which we are on track to enroll approximately 100 patients. This trial represents a crucial opportunity to demonstrate the potential of Descartes-08 to improve patient outcomes and redefine the standard-of-care for MG. Descartes-08's ease of use, including, flexible, convenient outpatient administration with no preconditioning chemotherapy, combined with deep and durable responses observed through 12 months following a single course of treatment, and a favorable safety profile, underscore our belief that Descartes-08 holds significant promise to deliver meaningful benefit to patients."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNAC
Wall Street analysts forecast RNAC stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 5.850
Low
16.00
Averages
35.00
High
44.00
Current: 5.850
Low
16.00
Averages
35.00
High
44.00
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cartesian Therapeutics Reports Disappointing FY Earnings with Significant Revenue Decline
- Earnings Miss: Cartesian Therapeutics reported a FY GAAP EPS of -$5.02, missing expectations by $2.67, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company posted revenue of $2.79 million, a staggering 92.8% year-over-year decrease, although it beat estimates by $0.82 million; this drastic decline reflects a sharp reduction in market demand, potentially leading to future liquidity issues.
- Strong Cash Position: As of December 31, 2025, Cartesian had $126.9 million in cash, cash equivalents, and restricted cash, which is expected to support planned operations, including the ongoing Phase 3 AURORA trial and the initiation of the Phase 2 TRITON trial, through mid-2027.
- Trial Progress: Despite disappointing financial results, Cartesian continues to advance its AURORA and TRITON trials, demonstrating ongoing investment in R&D that may lay the groundwork for future product launches and market recovery.
See More
Cartesian Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On February 2, 2026, Cartesian Therapeutics granted stock options for a total of 12,050 shares to two new employees at an exercise price of $6.79, reflecting the company's commitment to incentivizing new talent.
- Option Structure: The options will vest 25% on February 2, 2027, followed by monthly vesting over the next 36 months, fully vesting by February 2, 2030, indicating the company's focus on long-term employee retention.
- Compliance and Incentive Plan: The stock options were granted under Nasdaq Listing Rule 5635(c)(4) as a material inducement for the employees' entry into the company, aimed at attracting and retaining key talent to enhance competitive positioning.
- Clinical Development Context: Cartesian Therapeutics is pioneering cell therapy for autoimmune diseases, with its lead asset Descartes-08 in Phase 3 trials for myasthenia gravis, showcasing the company's innovative potential and market prospects in the biotechnology sector.
See More
Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases
- Clinical Trial Progress: Cartesian's Descartes-08 is on track in the Phase 3 AURORA trial for myasthenia gravis, aiming to enroll approximately 100 participants to assess its impact on MG Activities of Daily Living, which could significantly enhance treatment outcomes and expand market share if successful.
- FDA Approval for New Indication: The IND application for Descartes-08 in myositis has been accepted by the FDA, with plans to initiate a Phase 2 trial in the first half of 2026, providing a potential opportunity for a single pivotal trial that would further strengthen its competitive position in autoimmune diseases.
- Pediatric Trial Initiation: The Phase 1/2 pediatric trial of Descartes-08 has been initiated for juvenile dermatomyositis, with the FDA granting Rare Pediatric Disease Designation, indicating the company's strategic focus on the pediatric autoimmune disease market.
- Funding Support Plan: Current cash resources are expected to support the completion of the ongoing Phase 3 trial for Descartes-08 and the initiation of the Phase 2 myositis trial through mid-2027, ensuring continued investment in R&D and maintaining market competitiveness.
See More
Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases
- Clinical Trial Progress: Enrollment in the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis is on track, with plans to initiate a Phase 2 trial for myositis in the first half of 2026, showcasing the company's ongoing innovation in autoimmune disease treatment.
- FDA Approval: The IND application for Descartes-08 targeting myositis has been accepted by the FDA, with a randomized double-blind trial planned for the first half of 2026, potentially paving the way for a single pivotal trial and enhancing market competitiveness.
- Funding Support: The company expects its current cash resources to support planned operations, including the completion of the Phase 3 trial for Descartes-08, through mid-2027, ensuring continuity and stability in its R&D efforts.
- Pediatric Trial Launch: The Phase 1/2 trial of Descartes-08 in juvenile dermatomyositis has been initiated, with the FDA granting Rare Pediatric Disease Designation, indicating the company's strategic positioning in treating autoimmune diseases in children.
See More
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
- Positive Study Results: Johnson & Johnson's JASMINE study involving 228 systemic lupus erythematosus patients met its primary endpoint, demonstrating statistically significant improvement in patient response rates at Week 24 compared to placebo, marking the first positive results for an investigational FcRn blocker in this indication.
- Safety Profile Consistent: Nipocalimab exhibited a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified, thereby establishing a solid foundation for further clinical development.
- Significant Market Potential: With systemic lupus erythematosus affecting an estimated 3 to 5 million people globally, including 450,000 in the U.S., the positive study results could provide a strong competitive advantage for Johnson & Johnson in this market.
- Clear Next Steps: Following the positive Phase 2 results, Johnson & Johnson plans to initiate a Phase 3 program for Nipocalimab, aiming to further validate its therapeutic potential in systemic lupus erythematosus, which could drive future revenue growth for the company.
See More
Cartesian Therapeutics Grants 7,350 Stock Options to New Employees at $6.76 Exercise Price
- Employee Incentive Program: On January 2, 2026, Cartesian Therapeutics granted 7,350 stock options to two new employees at an exercise price of $6.76, reflecting the company's commitment to talent acquisition aimed at enhancing team stability and innovation capacity.
- Option Structure: The options will vest 25% on January 2, 2027, followed by equal monthly installments over 36 months, ensuring full vesting by January 2, 2030, which aligns employee interests with long-term company growth.
- Compliance and Strategy: This grant complies with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employee entry, demonstrating the company's strategic intent to attract and retain key talent in a competitive market.
- Clinical Development Context: Cartesian focuses on cell therapy for autoimmune diseases and is advancing its lead asset Descartes-08 in clinical development, with talent incentives expected to enhance R&D efficiency and expedite product market entry.
See More
Cartesian Therapeutics Reports Disappointing FY Earnings with Significant Revenue Decline
- Earnings Miss: Cartesian Therapeutics reported a FY GAAP EPS of -$5.02, missing expectations by $2.67, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company posted revenue of $2.79 million, a staggering 92.8% year-over-year decrease, although it beat estimates by $0.82 million; this drastic decline reflects a sharp reduction in market demand, potentially leading to future liquidity issues.
- Strong Cash Position: As of December 31, 2025, Cartesian had $126.9 million in cash, cash equivalents, and restricted cash, which is expected to support planned operations, including the ongoing Phase 3 AURORA trial and the initiation of the Phase 2 TRITON trial, through mid-2027.
- Trial Progress: Despite disappointing financial results, Cartesian continues to advance its AURORA and TRITON trials, demonstrating ongoing investment in R&D that may lay the groundwork for future product launches and market recovery.
See More
Cartesian Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On February 2, 2026, Cartesian Therapeutics granted stock options for a total of 12,050 shares to two new employees at an exercise price of $6.79, reflecting the company's commitment to incentivizing new talent.
- Option Structure: The options will vest 25% on February 2, 2027, followed by monthly vesting over the next 36 months, fully vesting by February 2, 2030, indicating the company's focus on long-term employee retention.
- Compliance and Incentive Plan: The stock options were granted under Nasdaq Listing Rule 5635(c)(4) as a material inducement for the employees' entry into the company, aimed at attracting and retaining key talent to enhance competitive positioning.
- Clinical Development Context: Cartesian Therapeutics is pioneering cell therapy for autoimmune diseases, with its lead asset Descartes-08 in Phase 3 trials for myasthenia gravis, showcasing the company's innovative potential and market prospects in the biotechnology sector.
See More
Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases
- Clinical Trial Progress: Cartesian's Descartes-08 is on track in the Phase 3 AURORA trial for myasthenia gravis, aiming to enroll approximately 100 participants to assess its impact on MG Activities of Daily Living, which could significantly enhance treatment outcomes and expand market share if successful.
- FDA Approval for New Indication: The IND application for Descartes-08 in myositis has been accepted by the FDA, with plans to initiate a Phase 2 trial in the first half of 2026, providing a potential opportunity for a single pivotal trial that would further strengthen its competitive position in autoimmune diseases.
- Pediatric Trial Initiation: The Phase 1/2 pediatric trial of Descartes-08 has been initiated for juvenile dermatomyositis, with the FDA granting Rare Pediatric Disease Designation, indicating the company's strategic focus on the pediatric autoimmune disease market.
- Funding Support Plan: Current cash resources are expected to support the completion of the ongoing Phase 3 trial for Descartes-08 and the initiation of the Phase 2 myositis trial through mid-2027, ensuring continued investment in R&D and maintaining market competitiveness.
See More
Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases
- Clinical Trial Progress: Enrollment in the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis is on track, with plans to initiate a Phase 2 trial for myositis in the first half of 2026, showcasing the company's ongoing innovation in autoimmune disease treatment.
- FDA Approval: The IND application for Descartes-08 targeting myositis has been accepted by the FDA, with a randomized double-blind trial planned for the first half of 2026, potentially paving the way for a single pivotal trial and enhancing market competitiveness.
- Funding Support: The company expects its current cash resources to support planned operations, including the completion of the Phase 3 trial for Descartes-08, through mid-2027, ensuring continuity and stability in its R&D efforts.
- Pediatric Trial Launch: The Phase 1/2 trial of Descartes-08 in juvenile dermatomyositis has been initiated, with the FDA granting Rare Pediatric Disease Designation, indicating the company's strategic positioning in treating autoimmune diseases in children.
See More
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
- Positive Study Results: Johnson & Johnson's JASMINE study involving 228 systemic lupus erythematosus patients met its primary endpoint, demonstrating statistically significant improvement in patient response rates at Week 24 compared to placebo, marking the first positive results for an investigational FcRn blocker in this indication.
- Safety Profile Consistent: Nipocalimab exhibited a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified, thereby establishing a solid foundation for further clinical development.
- Significant Market Potential: With systemic lupus erythematosus affecting an estimated 3 to 5 million people globally, including 450,000 in the U.S., the positive study results could provide a strong competitive advantage for Johnson & Johnson in this market.
- Clear Next Steps: Following the positive Phase 2 results, Johnson & Johnson plans to initiate a Phase 3 program for Nipocalimab, aiming to further validate its therapeutic potential in systemic lupus erythematosus, which could drive future revenue growth for the company.
See More
Cartesian Therapeutics Grants 7,350 Stock Options to New Employees at $6.76 Exercise Price
- Employee Incentive Program: On January 2, 2026, Cartesian Therapeutics granted 7,350 stock options to two new employees at an exercise price of $6.76, reflecting the company's commitment to talent acquisition aimed at enhancing team stability and innovation capacity.
- Option Structure: The options will vest 25% on January 2, 2027, followed by equal monthly installments over 36 months, ensuring full vesting by January 2, 2030, which aligns employee interests with long-term company growth.
- Compliance and Strategy: This grant complies with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employee entry, demonstrating the company's strategic intent to attract and retain key talent in a competitive market.
- Clinical Development Context: Cartesian focuses on cell therapy for autoimmune diseases and is advancing its lead asset Descartes-08 in clinical development, with talent incentives expected to enhance R&D efficiency and expedite product market entry.
See More
